Compared with CLL patients treated with CAR T cells without IBR, CAR T cells with concurrent ibrutinib were associated with lower CRS severity, with lower serum concentrations of CRS-associated cytokines, MCP-1, soluble IL-2Rα, and IL-6 despite comparable in vivo CAR T cell expansion. This evidence concerns the gene IL6 and congenital rubella syndrome.